Estimating the shared heritability between cancers will inform common biological mechanisms and future studies. Lindström and colleagues estimated the pair-wise genetic correlation between breast, colorectal, lung, ovarian, pancreatic, and prostate cancer using data on 66,958 cases and 70,665 controls of European ancestry. The authors observed genetic correlations between pancreatic and colorectal cancer, lung and colorectal cancer, lung and breast cancer, and colorectal and breast cancer. In contrast, prostate cancer did not share an appreciable proportion of heritability with other cancers. Overall, the results indicate modest genetic correlations between cancers; in particular, breast, colorectal, and lung cancer share some degree of genetic basis.Breast cancer is the most common cancer in young women worldwide. Risk factors for breast cancer may differ before and after menopause, but few cohort studies have sufficient numbers of cases among premenopausal women to study potential risk factors adequately in this group. To address this gap, the Premenopausal Breast Cancer Collaborative Group pooled data from 20 cohorts internationally, including a total of 21,766 incident breast cancers diagnosed among 1,030,761 women before age 55. Initial aims focused on the role of adiposity, physical activity, and recent pregnancy, with opportunities for collaborative research on other hypotheses.This study by Niu and colleagues reported the development of one stool DNA test with methylated Syndecan-2 gene for the early detection of colorectal neoplasia. The authors evaluated the test in 497 stool samples, and found that it could detect 81.1% of colorectal cancers and 58.2% of advanced adenomas at a specificity of 93.3%. Furthermore, they also proved that the performance of this stool test was not affected by common interfering substances except berberine. This novel test would serve as an alternative method for screening colorectal neoplasia.Approximately 72 percent of oropharyngeal cancers are attributable to infection with human papillomavirus (HPV). Only 41% of Texas girls and 24% of boys ages 13 to 17 had completed the HPV vaccination series in 2015. The treatment costs saved by preventing future cases of oropharyngeal cancer is important for decisions about investments to increase the HPV immunization rate. We estimated the average two-year healthcare cost per incident case in Texas from the 2011–2014 Truven MarketScan Commercial Claims and Encounter Database. The cost was $160,639 among 467 patients, compared with $20,890 for 467 propensity score matched controls. The difference represents potential savings per case avoided by HPV immunization.